Anti-Human CD38 (Daratumumab) – Fc Muted™

Anti-Human CD38 (Daratumumab) – Fc Muted™

Product No.: LT2505

- -
- -
Product No.LT2505
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
Anti CD38, HuMax-CD38
Human IgG1κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Expression Host
HEK-293 Cells
Human CD38
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
≥95% by SDS Page
≥95% monomer by analytical SEC
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
2-8°C Wet Ice
Additional Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Daratumumab. This product is for research use only. Daratumumab activity is directed against human CD38.
Antigen Distribution
CD38 is expressed on plasma cells, other lymphoid and myeloid cell populations, natural killer cells, B cells, activated T cells, some peripheral regulatory T cells, monocytes, lymph node germinal center lymphoblasts, intrafollicular cells, dendritic cells, erythrocytes, platelets, committed stem cells, Purkinje cells, neurofibrillary tangles in the brain, epithelial cells in the prostate, β‐cells in the pancreas, retinal cells in the eye, and sarcolemma of smooth and striated muscle. CD38 can also be detected on early osteoclast progenitors but not on osteoblasts and mature osteoclasts. CD38 expression is very high and uniform on all malignant cells in multiple myeloma. While generally found on the plasma membrane, CD38 has also been detected in the cytosol or nucleus in brain, pancreatic acinar cells, smooth muscle, and osteoclasts.
CD38 is a type II transmembrane glycoprotein that functions as an adhesion molecule with ectoenzymatic activities that contribute to intracellular calcium mobilization1, 2. Dysregulation is associated with a number of diseases, including HIV, autoimmune, type II diabetes mellitus, osteoporosis, and hematological malignancies such as multiple myeloma (MM)1, a neoplasm characterized by clonal expansion of malignant plasma cells2. CD38 is a target of MM immunotherapy, and, in 2015, the US Food and Drug Administration approved the use of daratumumab for MM treatment3.

Daratumumab kills CD38-expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking3, 4 as well as by immune-mediated tumor cell lysis via complement dependent cytotoxicity (CDC)5, antibody dependent cell mediated cytotoxicity (ADCC)5, and antibody dependent cellular phagocytosis (ADCP)3, 4, 6. Daratumumab also modulates CD38 enzymatic activities, blunting cyclase activity and enhancing hydrolase activity, resulting in decreased Ca2+ mobilization and reduced downstream signaling1. Furthermore, subsets of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs), and B cells (CD38+Bregs) are decreased by daratumumab3, and CD38 is uniformly removed from the surface of red blood cells without inducing detectable hemolysis7.

Daratumumab was generated by immunizing HuMAb-mice with purified HA-CD38 recombinant protein alone or alternating with CD38-transfected NIH-3T3 cells5. Mouse splenocytes and lymph node cells were isolated, fused with SP2/0 myeloma cells, and tested for binding to CHO-CD38 cells. The daratumumab epitope maps to two β-strands containing amino acids 233–246 and 267–280 of CD38. Binding to CD38 is completely abolished when the serine at position 274 is replaced with phenylalanine. Daratumumab does not bind to cynomolgus CD38.

Daratumumab clone AL9, a non-therapeutic biosimilar antibody for research use only was developed recombinantly and has the same variable regions as the original therapeutic.

Antigen Details

CD38 Receptor, Enzyme
NCBI Gene Bank ID
Research Area
Signal Transduction

References & Citations

1. van de Donk NW, Janmaat ML, Mutis T, et al. Immunol Rev. 270(1):95-112. 2016.
2. Morandi F, Horenstein AL, Costa F, et al. Front Immunol. 9:2722. 2018.
4. Phipps C, Chen Y, Gopalakrishnan S, et al. Ther Adv Hematol 6(3):120-127. 2015.
5. de Weers M, Tai YT, van der Veer MS, et al. J Immunol. 186(3):1840-1848. 2011.
6. Overdijk MB, Verploegen S, Bögels M, et al. MAbs. 7(2):311-321. 2015.
7. Sullivan HC, Gerner-Smidt C, Nooka AK, et al. Blood. 129(22):3033-3037. 2017.
8. Kong S-Y, Li X-F, Nahar S, et al. Blood. 116(21):3013. 2010.
9. Marco Jansen JH, Boross P, Overdijk MB, et al. Blood. 120(21):2974. 2012.
10. Plesner T, Lokhorst H, Gimsing P, et al. Blood. 120(21):73. 2012.
11. Krejcik J, Casneuf T, Nijhof IS, et al. Blood. 128(3):384-394. 2016.
12. Naeimi Kararoudi M, Nagai Y, Elmas E, et al. Blood. 136(21):2416-2427. 2020.
Indirect Elisa Protocol
Flow Cytometry
Immunoprecipitation Protocol
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.